Fresh Tracks Therapeutics jumps on lead drug study progress

Fresh Tracks Therapeutics

13/09/2022 16:29

** Shares of drug Developer Fresh Tracks Therapeutics Inc
 FRTX.O  climb 18.1% to $2.49 
    ** FRTX start second dosing cohort in an ongoing early-stage
study of its lead drug candidate, FRTX-02, in Canada
 urn:newsml:reuters.com:*:nGNX56CdKS
    ** Study is designed to test different dosing regimen of
FRTX-02 capsules in healthy adult subjects as well as patients
with atopic dermatitis
    ** Co expects results from the study by early 2023
    ** Including session gains, stock has lost ~75% YTD

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))